Evidence map›Paper›PMID 19747868›Full record

Trial reportMolecular genetics and metabolism2009

Reassessment of phenylalanine tolerance in adults with phenylketonuria is needed as body mass changes.

Erin L MacLeod, Sally T Gleason, Sandra C van Calcar, Denise M Ney

Registry-linked trialOpen access · greenAbstract readClinical Trial
In one paragraph

Trial report in Molecular genetics and metabolism, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04969809 (Comparison of Atherogenic Risk Factors and Efficacy of Nutritional Treatment Among Adult Phenylketonuria Patients), which is not on this map. Cited by 24 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 2 pooled it
2.9field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04969809 nanot yet recruitingnot on this mapstarted 2021, after this paper: background citation

Comparison of Atherogenic Risk Factors and Efficacy of Nutritional Treatment Among Adult Phenylketonuria Patients

TypeinterventionalSponsorUniversity Medical Centre LjubljanaRan2021 to 2026Enrolled50ConditionsPhenylketonurias, Nutritional and Metabolic DiseasesArmsUltrasound of the jugular veins, addition of phenylalanine-free protein substitutes
3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Mapping the Severity of Phenylalanine Hydroxylase Deficiency.Journal of inherited metabolic disease · 2026
    Review
  6. Article
  7. Article
  8. Review
  9. PKU dietary handbook to accompany PKU guidelines.Orphanet journal of rare diseases · 2020
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Erin L MacLeodDepartment of Nutritional Sciences, 1415 Linden Drive, University of Wisconsin, Madison, WI 53705, USA.
Sally T Gleason
Sandra C van Calcar
Denise M Ney
University of Wisconsin–Madison · US

Funding

WISCONSIN CENTER ON MENTAL RETARDATION: CORE SUPPORTP30HD003352 · NICHD · UNIVERSITY OF WISCONSIN-MADISON · PI DAVIDSON, RICHARD J · 1985 to 2015
$25.2M
Dietary Control of PKU with Glycomacropeptide from WheyR03DK071534 · NIDDK · UNIVERSITY OF WISCONSIN-MADISON · PI NEY, DENISE M · 2005 to 2007
$308k
NICHD NIH HHS P30 HD003352NICHD NIH HHS P30-HD-03352NIDDK NIH HHS R03 DK071534NIDDK NIH HHS R03-DK-071534
6 · The paper itself

Abstract

Lifelong treatment of phenylketonuria (PKU) includes a phenylalanine (phe) restricted diet that provides sufficient phe for growth and maintenance plus phe-free amino acid formula to meet requirements for protein, energy and micronutrients. Phe tolerance (mg phe/kg body weight/day) is the amount of phe those with PKU can consume and maintain acceptable blood phe levels; it requires individual assessment because of varying phenylalanine hydroxylase activity. The objective was to reassess phe tolerance in eight adults with PKU considering phe requirements, blood phe levels, genotype and phe tolerance at 5 years of age. Subjects had not received a personalized assessment of phe tolerance in several years, and five subjects were overweight, body mass index (BMI) 25-28. With the guidance of a metabolic dietitian, seven subjects increased phe tolerance (by 15-173%) without significantly increasing blood phe concentration. Increased phe tolerance was associated with both improved dietary compliance and inadequate phe intake at the onset of the protocol compared with current requirements. Improved dietary compliance reflected increased consumption of protein equivalents from amino acid formula and increased frequency of formula intake, from 2.2 to 3 times per day. Predictors of higher final phe tolerance following reassessment included being male and having a lower BMI (R(2)=0.588). This suggests that the rising trend of overweight and obesity may affect assessment of phe tolerance in adults. Therefore, interaction with the metabolic dietitian to reassess phe tolerance in relation to body mass is essential throughout adulthood to insure adequate intake of phe to support protein synthesis and prevent catabolism.

Indexed as

Adaptation, PhysiologicalBody WeightAdultDietFemaleGenotypeHumansMalePhenylalaninePhenylketonuriasYoung AdultPhenylalanine

Identifiers

PMID19747868
PMCPMC2783926
OpenAlexW1976337547

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.